O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+11.03%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$5.48B
AUM Growth
+$5.48B
(+8.5%)
Cap. Flow
+$63.8M
Cap. Flow
% of AUM
1.16%
Top 10 Holdings %
Top 10 Hldgs %
32.95%
Holding
132
New
15
Increased
25
Reduced
27
Closed
11
Top Buys
| 1 |
SLRN
ACELYRIN
SLRN
|
$111M |
| 2 |
United Therapeutics
UTHR
|
$88.7M |
| 3 |
Baxter International
BAX
|
$82.6M |
| 4 |
Madrigal Pharmaceuticals
MDGL
|
$74.3M |
| 5 |
Cigna
CI
|
$45.2M |
Top Sells
| 1 |
Verastem
VSTM
|
$111M |
| 2 |
Bristol-Myers Squibb
BMY
|
$54.5M |
| 3 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
$47M |
| 4 |
BLU
BELLUS Health Inc.
BLU
|
$36.8M |
| 5 |
Progyny
PGNY
|
$33.3M |
Sector Composition
| 1 | Healthcare | 97.46% |
| 2 | Industrials | 1.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
TG Therapeutics
TGTX
$5.12B
| – | – |
0
| – | – |
|
127
SPDR S&P Biotech ETF
XBI
$5.32B
| – | – |
-274,000
| Closed | -$20.9M |
|
|
KDNY
128
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| – | – |
-2,029,300
| Closed | -$47M |
|
|
BLU
129
DELISTED
BELLUS Health Inc.
BLU
| – | – |
-5,108,900
| Closed | -$36.8M |
|